Drug Patents owned by Incyte Corp

1. List of Jakafi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8415362 INCYTE CORP Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Dec, 2027

(4 years from now)

US7598257 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
Dec, 2027

(4 years from now)

US8722693 INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079912 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
Dec, 2026

(3 years from now)

US9814722 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
Dec, 2026

(3 years from now)

US9814722

(Pediatric)

INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
Jun, 2027

(4 years from now)

US9079912

(Pediatric)

INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
Jun, 2027

(4 years from now)

US10016429 INCYTE CORP Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

US8829013 INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

US8822481 INCYTE CORP Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

US7598257

(Pediatric)

INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
Jun, 2028

(5 years from now)

US8415362

(Pediatric)

INCYTE CORP Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Jun, 2028

(5 years from now)

US8722693

(Pediatric)

INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Dec, 2028

(5 years from now)

US8822481

(Pediatric)

INCYTE CORP Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Dec, 2028

(5 years from now)

US8829013

(Pediatric)

INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Dec, 2028

(5 years from now)

US10016429

(Pediatric)

INCYTE CORP Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Dec, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Sep 22, 2024
Orphan Drug Exclusivity (ODE) Sep 22, 2028
Pediatric Exclusivity (PED) Nov 24, 2026

Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient

Market Authorisation Date: 16 November, 2011

Treatment: For treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; For treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; For treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; For treatment of steroid-refractory acute graft-versus-host disease (agvhd); For the treatment of polycythemia vera; For the treatment of intermediate or high-risk myelofibrosis; Use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2.

Dosage: TABLET;ORAL

How can I launch a generic of JAKAFI before it's patent expiration?
More Information on Dosage

2. List of Opzelura drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8415362 INCYTE CORP Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Dec, 2027

(4 years from now)

US7598257 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
Dec, 2027

(4 years from now)

US8722693 INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079912 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
Dec, 2026

(3 years from now)

US10639310 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Dec, 2026

(3 years from now)

US9974790 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
Dec, 2026

(3 years from now)

US9079912

(Pediatric)

INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
Jun, 2027

(4 years from now)

US9974790

(Pediatric)

INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
Jun, 2027

(4 years from now)

US10639310

(Pediatric)

INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Jun, 2027

(4 years from now)

US10610530 INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

US8822481 INCYTE CORP Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

US7598257

(Pediatric)

INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
Jun, 2028

(5 years from now)

US8415362

(Pediatric)

INCYTE CORP Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Jun, 2028

(5 years from now)

US8722693

(Pediatric)

INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Dec, 2028

(5 years from now)

US8822481

(Pediatric)

INCYTE CORP Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Dec, 2028

(5 years from now)

US10610530

(Pediatric)

INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Dec, 2028

(5 years from now)

US11219624 INCYTE CORP Topical formulation for a JAK inhibitor
May, 2031

(8 years from now)

US10869870 INCYTE CORP Topical formulation for a JAK inhibitor
May, 2031

(8 years from now)

US10758543 INCYTE CORP Topical formulation for a JAK inhibitor
May, 2031

(8 years from now)

US10869870

(Pediatric)

INCYTE CORP Topical formulation for a JAK inhibitor
Nov, 2031

(8 years from now)

US10758543

(Pediatric)

INCYTE CORP Topical formulation for a JAK inhibitor
Nov, 2031

(8 years from now)

US11219624

(Pediatric)

INCYTE CORP Topical formulation for a JAK inhibitor
Nov, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Sep 21, 2024
New Indication (I) Jul 18, 2025
Pediatric Exclusivity (PED) Mar 21, 2025

Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient

Market Authorisation Date: 21 September, 2021

Treatment: For topical short-term, non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable

Dosage: CREAM;TOPICAL

More Information on Dosage

3. List of Pemazyre drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9611267 INCYTE CORP Substituted tricyclic compounds as FGFR inhibitors
Jan, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10131667 INCYTE CORP Substituted tricyclic compounds as FGFR inhibitors
Jun, 2033

(10 years from now)

US11466004 INCYTE CORP Solid forms of an FGFR inhibitor and processes for preparing the same
May, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 17, 2025
Orphan Drug Exclusivity (ODE) Apr 17, 2027
New Indication (I) Aug 26, 2025

Drugs and Companies using PEMIGATINIB ingredient

NCE-1 date: April, 2024

Market Authorisation Date: 17 April, 2020

Treatment: For the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement; Treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering once daily a tablet containing about 0.5 mg to about 10 mg of pemigatinib; Treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering pemigatinib qd for 14 days then not administering pemigatinib for 7 days in a 21-day cycle; Treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering pemigatinib in a daily dose of about 5 mg to about 20 mg

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in